Literature DB >> 18174904

Infections and IBD.

Peter M Irving1, Peter R Gibson.   

Abstract

An interaction between infection and IBD was identified soon after Crohn's disease and ulcerative colitis were first described. Since then it has become apparent that infectious agents are involved with both the etiopathogenesis and clinical course of IBD on several levels. Whilst our understanding of this interplay is incomplete, it is clear that infections can initiate both the onset and relapse of IBD. Furthermore, the disease process itself predisposes patients to certain infections, and many drugs used to treat IBD also increase the risk of infectious complications. Attempts to establish the relative infectious risks associated with the drugs used to treat IBD remain in an early stage; but it seems that the greatest risks relate to the combined use of immunomodulating agents rather than to individual drugs. The risk of infections in patients with IBD might also be exacerbated by underuse of, and perhaps substandard response to, vaccinations. It is axiomatic that physicians treating patients with IBD must be aware of these infectious risks and of strategies to minimize them. Meanwhile, intriguing advances in the use of parasitic agents as a treatment for ulcerative colitis and Crohn's disease have introduced a new angle to the interplay between infections and IBD.

Entities:  

Mesh:

Year:  2008        PMID: 18174904     DOI: 10.1038/ncpgasthep1004

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN: 1743-4378


  25 in total

1.  Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets.

Authors:  Qing Xiong; Nicola Ancona; Elizabeth R Hauser; Sayan Mukherjee; Terrence S Furey
Journal:  Genome Res       Date:  2011-09-22       Impact factor: 9.043

2.  Management of the returning traveler with diarrhea.

Authors:  Philippe P H de Saussure
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

3.  Alpha-lipoic acid attenuates trinitrobenzene sulfonic acid-induced ulcerative colitis in mice.

Authors:  Jing Sun; Huijing Zhang; Lin Guan; Huan Zhou; Mingjun Sun
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  Management of abdominal and pelvic abscess in Crohn's disease.

Authors:  Robert J Richards
Journal:  World J Gastrointest Endosc       Date:  2011-11-16

5.  Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology.

Authors:  Manolis Roulis; Maria Armaka; Menelaos Manoloukos; Maria Apostolaki; George Kollias
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-14       Impact factor: 11.205

Review 6.  T cells and intestinal commensal bacteria--ignorance, rejection, and acceptance.

Authors:  Jiani N Chai; You W Zhou; Chyi-Song Hsieh
Journal:  FEBS Lett       Date:  2014-07-02       Impact factor: 4.124

7.  Latent cytomegalovirus infection exacerbates experimental colitis.

Authors:  Chukwuma Onyeagocha; Mohammad S Hossain; Amrita Kumar; Rheinallt M Jones; John Roback; Andrew T Gewirtz
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

8.  Fc gamma receptor signaling in mast cells links microbial stimulation to mucosal immune inflammation in the intestine.

Authors:  Xiao Chen; Bai-Sui Feng; Peng-Yuan Zheng; Xue-Qing Liao; Jasmine Chong; Shang-Guo Tang; Ping-Chang Yang
Journal:  Am J Pathol       Date:  2008-10-30       Impact factor: 4.307

Review 9.  Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders.

Authors:  Grace Y Lam; Brendan P Halloran; Anthea C Peters; Richard N Fedorak
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

10.  Oh my aching gut: irritable bowel syndrome, Blastocystis, and asymptomatic infection.

Authors:  Kenneth F Boorom; Huw Smith; Laila Nimri; Eric Viscogliosi; Gregory Spanakos; Unaiza Parkar; Lan-Hua Li; Xiao-Nong Zhou; Ulgen Z Ok; Saovanee Leelayoova; Morris S Jones
Journal:  Parasit Vectors       Date:  2008-10-21       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.